Results 91 to 100 of about 128,263 (274)

Clinical features of Stevens — Johnson syndrome and toxic epidermal necrolysis: An observational cohort retrospective study

open access: yesКубанский научный медицинский вестник
Background. Stevens — Johnson syndrome and toxic epidermal necrolysis are severe diseases featuring lesions of the mucous membranes and skin, with a possible lethal outcome. These diseases are most often triggered by various infections and medications, e.
G. M. Nurtdinova   +6 more
doaj   +1 more source

Ivermectin induced Steven–Johnsons syndrome: case report

open access: yesBMC Research Notes, 2017
Background Stevens–Johnson syndrome is one of the manifestations of mucocutaneous adverse drug reactions. Although antimicrobials are responsible for greater than 50% of these adverse drug reactions, there is no documented case implicating ivermectin as ...
Desmond Aroke   +5 more
doaj   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer   +3 more
wiley   +1 more source

Phenytoin-induced Stevens–Johnson syndrome with myocarditis: a rare case report

open access: yes, 2017
Ashwin Kodliwadmath Department of Medicine, Belgaum Institute of Medical Sciences, Belgaum, India Abstract: Stevens–Johnson syndrome (SJS) is an acute life-threatening mucocutaneous reaction caused by excessive necrosis and detachment of the ...
Kodliwadmath A
core  

Stevens - Johnson Syndrome Induced by Sorafenib for Hepatocellular Carcinoma [PDF]

open access: yes, 2016
Background: Sorafenib is a new therapeutic agent being used in hepatocellular carcinoma, renal cell carcinoma and malignant melanoma. The most frequently seen cutaneous side effects due to sorafenib are erythema, exfoliative dermatitis, acne vulgaris and
Chakiri R   +3 more
core   +1 more source

Data_Sheet_1_Case report: Development of vanishing bile duct syndrome in Stevens-Johnson syndrome complicated by hemophagocytic lymphohistiocytosis.pdf

open access: yes, 2022
BackgroundVanishing bile duct syndrome is a rare drug-induced disease characterized by cholestasis and ensuing ductopenia. Dermatological manifestations of drug hypersensitivity such as Stevens-Johnson syndrome and toxic epidermal necrolysis may also ...
Chia-Yu Chu (320225)   +2 more
core   +1 more source

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States.

open access: yesJournal of Investigative Dermatology, 2018
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, severe mucocutaneous reaction with few large cohorts reported. This multicenter retrospective study included patients with SJS/TEN seen by inpatient consultative dermatologists at ...
R. Micheletti   +42 more
semanticscholar   +1 more source

Stevens-Johnson induced by imiquimod 5% cream: a case report

open access: yesDermatology Reports
Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas and anogenital warts. Severe systemic side effects associated to imiquimod 5% cream are rare, although few cases of erythema multiforme and Stevens ...
Ilaria Trave   +5 more
doaj   +1 more source

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1137-1161, July 2026.
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda   +31 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy